
Pharmaceutical Law Attorney - Medications
Medicines are the most heavily regulated product under European law: from clinical research to pharmacovigilance, each stage of their lifecycle is governed by a precise body of regulations—the French Public Health Code, Directive 2001/83/EC, and European regulations—under the supervision of the French National Agency for Medicines and Health Products Safety (ANSM) and the European Medicines Agency (EMA). Our firm assists pharmaceutical companies, marketing authorization holders, distributors, and healthcare startups at each of these stages, providing both advisory and litigation services.
Areas of intervention
Recherche & Développement
-
Contrats de collaboration, co-développement, licences, transfert de matériel biologique (MTA)
-
Contrats de recherche clinique (promoteur, investigateur, CRO) ; convention unique avec les établissements de santé
-
Relations avec les Comités de Protection des Personnes (CPP) et l’ANSM (règlement (UE) n° 536/2014, RIPH)
Statut et qualification du produit
Drug by function or presentation; borderline products (food supplement, medical device, cosmetic)
Special statuses: MTI, preparations, herbal medicines
Securing regulatory positioning before launch
Commercialisation
Manufacturing, co-marketing or co-promotion agreements between manufacturers
Distribution contracts, general terms and conditions of sale and pricing policy, relationships with intermediaries
International agreements, import/export, parallel imports
Vigilance, ruptures and inspections
Pharmacovigilance: system organization, reporting, urgent safety measures
Quality defects, batch recalls, crisis management
Stockouts: coverage obligations, safety stocks, shortage management plans for MITM, ANSM relations
Santé numérique
Clinical data from research and real-life data
GDPR compliance applied to healthcare, patient consent, HDS hosting
Digital projects: disease awareness, Patient Support Programs, AI tools
Établissements pharmaceutiques et opérations
-
Création d’un établissement pharmaceutique ; statuts d’exploitant, fabricant, dépositaire, grossiste-répartiteur
-
Enregistrement auprès des autorités (ANSM, ARS, EMA...)
-
Management de la qualité (BPF/BPD), contrats de logistique et supply chain, quality agreements
Accès au marché
-
Autorisations de mise sur le marché : procédures, variations, transferts, renouvellements
-
Accès précoce et accès compassionnel
-
Prix et remboursement (CEPS, Commission de la transparence) ; accès hospitalier, marchés publics, référencement
Publicité et information médicale
Advertising to the public and healthcare professionals: PM/PP visas, ANSM filings
Validation of promotional materials, medical information, congresses, samples
Charter and certification of promotional information
Compliance / Encadrement des avantages
DMOS/LEA (anti-gifts) and transparency of conflicts of interest
Ethics and compliance: relations with HCPs, HCOs and patient associations (POs); coordination with Sapin II
Creation and updating of internal documents (Guidebook, SOPs, guidelines); training, internal audits and investigations
The drug
A strictly regulated product whose status is defined according to its function or presentation.
The firm assists pharmaceutical operators — laboratories, operators, custodians, wholesale distributors and health start-ups — on all compliance and safety issues related to their products.
Accurate knowledge of the applicable regulations, derived from the public health code and European Union law, makes it possible to carry out the necessary compliance measures and to prevent the problems that arise from them: product qualification, marketing authorization, advertising, distribution, pharmacovigilance.
It also allows the firm to support operators in the context of ANSM health control and policing measures, as well as DGCCRF investigations.
A drug is any substance presented as having curative or preventive properties, or that can be used to restore, correct or modify physiological functions.
This deliberately broad definition has major consequences: a product classified as a medicinal product cannot be marketed without a marketing authorization (MA), issued by the ANSM (French National Agency for Medicines and Health Products Safety) or by the European Commission after evaluation by the EMA (European Medicines Agency). This leads to specific rules governing manufacturing (GMP), wholesale distribution (GDP), promotion—advertising for medicinal products is among the most strictly regulated—and the monitoring of adverse effects (pharmacovigilance).
